Luis Lara-Mejía: Early Resistance in ALK+ NSCLC Targeted with Alectinib and Bevacizumab Combo
Luis Lara-Mejía, Medical Oncologist Specialized in Thoracic Neoplasms at National Institute of Cancerology, posted on X:
“Proud to share our new publication in Nature Communications, led by Oscar Arrieta and an extraordinary team effort.
Alectinib + bevacizumab as 1L therapy in metastatic ALK+ NSCLC:
- ORR: 100%
- 12 and 36 month PFS: 97% and 64.2%
- 36-month intracranial PFS: 87.8%
- While not practice-changing yet, this phase II trial lays a solid foundation to explore antiangiogenic combinations in ALK+ NSCLC, especially in patients with poorer prognosis.
- Even in the lorlatinib era, early resistance remains a challenge.
Could combinations help us shift the curve earlier? Let’s keep asking. Let’s keep pushing.”
Title: Alectinib in combination with bevacizumab as first-line treatment in ALK-rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trial
Authors: Oscar Arrieta, Luis Lara-Mejía, Eduardo Rios-Garcia, Enrique Caballé-Perez, Luis Cabrera-Miranda, Maritza Ramos-Ramírez, David Dávila-Dupont, Andrés F. Cardona, Graciela Cruz-Rico, Jordi Remon, Alexandra Garcilazo-Reyes, Rafael Rosell
Read The Article at Nature Communications.
More Posts featuring NSCLC.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023